Search Results - "Tolcher, Anthony W."

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors by YAP, Timothy A, LI YAN, RIISNAES, Ruth, POPE, Lorna L, HEATON, Simon P, THOMAS, George, GARRETT, Michelle D, SULLIVAN, Daniel M, DE BONO, Johann S, TOLCHER, Anthony W, PATNAIK, Amita, FEAREN, Ivy, OLMOS, David, PAPADOPOULOS, Kyriakos, BAIRD, Richard D, DELGADO, Liliana, TAYLOR, Adekemi, LUPINACCI, Lisa

“…AKT signaling is frequently deregulated in human cancers. MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in…”
Get full text

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1 by TOLCHER, Anthony W, SARANTOPOULOS, John, KAISER, Brianne, MIN ZHU, HONGJIE DENG, FRIBERG, Greg, PUZANOV, Igor, PATNAIK, Amita, PAPADOPOULOS, Kyriakos, LIN, Chia-Chi, RODON, Jordi, MURPHY, Barbara, ROTH, Bruce, MCCAFFERY, Ian, GORSKI, Kevin S

“…To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human…”
Get full text

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor by Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, Patnaik, Amita

“…Background: Binimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined the maximum tolerated dose (MTD),…”
Get full text

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors by TOLCHER, Anthony W, MESSERSMITH, Wells A, BOYLAN, John F, XU, Zhi-Xin, KA WANG, KOEHLER, Astrid, SONG, James, MIDDLETON, Steven A, DEUTSCH, Jonathan, DEMARIO, Mark, KURZROCK, Razelle, WHELER, Jennifer J, MIKULSKI, Stanislaw M, PAPADOPOULOS, Kyriakos P, KWAK, Eunice L, GIBBON, Darlene G, PATNAIK, Amita, FALCHOOK, Gerald S, DASARI, Arvind, SHAPIRO, Geoffrey I

“…To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, pharmacodynamics, and evidence of antitumor activity of RO4929097, a gamma…”
Get full text

Antitumor activity in RAS-driven tumors by blocking AKT and MEK by Tolcher, Anthony W, Khan, Khurum, Ong, Michael, Banerji, Udai, Papadimitrakopoulou, Vassiliki, Gandara, David R, Patnaik, Amita, Baird, Richard D, Olmos, David, Garrett, Christopher R, Skolnik, Jeffrey M, Rubin, Eric H, Smith, Paul D, Huang, Pearl, Learoyd, Maria, Shannon, Keith A, Morosky, Anne, Tetteh, Ernestina, Jou, Ying-Ming, Papadopoulos, Kyriakos P, Moreno, Victor, Kaiser, Brianne, Yap, Timothy A, Yan, Li, de Bono, Johann S

“…KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244;…”
Get full text

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas by CHAWLA, Sant P, STADDON, Arthur P, RIVERA, Victor M, CLACKSON, Tim, LOEWY, John W, HALUSKA, Frank G, DEMETRI, George D, BAKER, Laurence H, SCHUETZE, Scott M, TOLCHER, Anthony W, D'AMATO, Gina Z, BLAY, Jean-Yves, MITA, Monica M, SANKHALA, Kamalesh K, BERK, Lori

“…Ridaforolimus is an inhibitor of mammalian target of rapamycin, an integral component of the phosphatidyl 3-kinase/AKT signaling pathway, with early evidence…”
Get full text

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors by MITA, Alain C, DENIS, Louis J, SEMIOND, Dorothée, BESENVAL, Michèle, TOLCHER, Anthony W, ROWINSKY, Eric K, DEBONO, Johann S, GOETZ, Andrew D, OCHOA, Leonel, FOROUZESH, Bahram, BEERAM, Muralidhar, PATNAIK, Amita, MOLPUS, Kathleen

“…Purpose: To assess the feasibility of administering XRP6258, a new taxane with a low affinity for the multidrug resistance 1 protein, as a 1-hour i.v. infusion…”
Get full text

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin by TOLCHER, Anthony W, MITA, Alain, KEATING, Anne, ANTONIA, Scott, LEWIS, Lionel D, GARRETT, Christopher R, TILL, Elizabeth, DAUD, Adil I, PATNAIK, Amita, PAPADOPOULOS, Kyri, TAKIMOTO, Chris, BARTELS, Pamela

“…To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a…”
Get full text

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1 by TOLCHER, Anthony W, MITA, Monica, HALPERN, Wendy, COREY, Alfred, COHEN, Roger B, MEROPOL, Neal J, VON MEHREN, Margaret, PATNAIK, Amita, PADAVIC, Kristin, HILL, Monique, MAYS, Theresa, MCCOY, Therese, FOX, Norma Lynn

“…To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal…”
Get full text

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies by MITA, Monica M, MITA, Alain C, KNOWLES, Heather, RIVERA, Victor M, KREISBERG, Jeff, BEDROSIAN, Camille L, TOLCHER, Anthony W, CHU, Quincy S, ROWINSKY, Eric K, FETTERLY, Gerald J, GOLDSTON, Michelle, PATNAIK, Amita, MATHEWS, Lesley, RICART, Alejandro D, MAYS, Theresa

“…This phase I trial was conducted to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of deforolimus (previously known as AP23573;…”
Get full text

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial by Blay, Jean-Yves, Prof, Pápai, Zsuzsanna, MD, Tolcher, Anthony W, Prof, Italiano, Antoine, MD, Cupissol, Didier, MD, López-Pousa, Antonio, MD, Chawla, Sant P, Bompas, Emmanuelle, MD, Babovic, Nada, MD, Penel, Nicolas, MD, Isambert, Nicolas, MD, Staddon, Arthur P, MD, Saâda-Bouzid, Esma, MD, Santoro, Armando, MD, Franke, Fabio A, MD, Cohen, Patrick, MD, Le-Guennec, Solenn, Demetri, George D, Prof

“…Summary Background Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when…”
Get full text

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors by Tolcher, Anthony W, Gordon, Michael, Mahoney, Kathleen M, Seto, Anna, Zavodovskaya, Marianna, Hsueh, Chia-Hsiang, Zhai, Shuyan, Tarnowski, Thomas, Jürgensmeier, Juliane M, Stinson, Susanna, Othman, Ahmed A, Chen, Tianling, Strauss, James

“…BackgroundCluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and…”
Get full text

Antibody drug conjugates: The dos and don'ts in clinical development by Tolcher, Anthony W.

“…Antibody Drug Conjugates (ADCs) entered clinical trials in the mid 1990s to selectively deliver cytotoxic chemotherapy to cancer cells with the goal to…”
Get full text

Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin by TOLCHER, Anthony W, SWEENEY, Christopher J, EATON, Cheryl, SILVER, Bruce A, MITA, Monica, PAPADOPOULOS, Kyri, PATNAIK, Amita, CHIOREAN, Elena G, MITA, Alain C, SANKHALA, Kamalesh, FURFINE, Eric, GOKEMEIJER, Jochem, IACONO, Lisa

“…To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322…”
Get full text

Technology Insight: cytotoxic drug immunoconjugates for cancer therapy by Tolcher, Anthony W, Ricart, Alejandro D

“…The successful introduction of genetically engineered human and chimeric immunoglobulin proteins has established monoclonal antibodies (mAbs) as a validated…”
Get full text

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies by WEINER, Louis M, BELLDEGRUN, Arie S, CRAWFORD, Jeffrey, TOLCHER, Anthony W, LOCKBAUM, Pamela, ARENDS, Rosalin H, NAVALE, Lynn, AMADO, Rafael G, SCHWAB, Gisela, FIGLIN, Robert A

“…Purpose: This phase 1 study evaluated the safety, pharmacokinetics, and activity of panitumumab, a fully human, IgG2 monoclonal antibody that targets the…”
Get full text

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer by TOLCHER, Anthony W, CHI, Kim, MURRAY, Nevin, FRANKEL, Stanley R, IZBICKA, Elzbieta, ROWINSKY, Eric, KUHN, John, GLEAVE, Martin, PATNAIK, Amita, TAKIMOTO, Chris, SCHWARTZ, Garry, THOMPSON, Ian, BERG, Kristin, D'ALOISIO, Susan

“…Purpose: To determine the antitumor activity and safety of oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the bcl-2 mRNA, with…”
Get full text

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors by Tolcher, Anthony W, Peng, Wei, Calvo, Emiliano

“…Molecular characterization of oncogenic mutations within genes in the MAPK and PI3K/AKT/mTOR pathways has led to the rational development of targeted…”
Get full text

Castration-resistant prostate cancer--hormone therapy redux by Tolcher, Anthony W, Cooper, Josh

Get full text

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors by Patnaik, Amita, Kang, S Peter, Rasco, Drew, Papadopoulos, Kyriakos P, Elassaiss-Schaap, Jeroen, Beeram, Muralidhar, Drengler, Ronald, Chen, Cong, Smith, Lon, Espino, Guillermo, Gergich, Kevin, Delgado, Liliana, Daud, Adil, Lindia, Jill A, Li, Xiaoyun Nicole, Pierce, Robert H, Yearley, Jennifer H, Wu, Dianna, Laterza, Omar, Lehnert, Manfred, Iannone, Robert, Tolcher, Anthony W

“…This phase I study evaluated the safety, maximum tolerated dose, antitumor activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients…”
Get full text